GE HealthCare announced that the NCCN Guidelines for Clinical Oncology now recommend FES PET for systemic staging in patients ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

The rollout marks a new chapter for men with prostate cancer, the most common cancer in Canadian men aside from skin cancer, ...

Podcast host and runner Ali Feller, known as Ali on the Run, revealed she was diagnosed with stage 4 breast cancer that ...

PET/CT is a useful tool to map out the possible sites where the cancer first originated. PET/CT is a form of hybrid imaging that combines computed tomography (CT), an anatomical imaging ...

Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64 Cu-SARTATE is safe and highly effective ...

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

This study is using a PET-CT scan after selective internal radiation therapy to find out where in the body the treatment has gone. It is open to people who have cancer that started in the liver or ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

30 patients of endometrial cancer were investigated and the FDG-PET imaging results were compared with CT and/or MRI and the results of postoperative histopathological results. [76] With regard to ...